Literature DB >> 23096919

Activation of the ERK1/2 pathway by the CaMEK gene via adeno-associated virus serotype 9 in cardiomyocytes.

Y-N Yang1, W-N Ji, Y-T Ma, X-M Li, B-D Chen, Y Xiang, F Liu.   

Abstract

Extracellular signal-regulated kinase (ERK1/2) is one of the mitogen-activated protein kinases, key components of the reperfusion injury salvage kinase pathway, which plays an important role in protecting the myocardium from lethal ischemia-reperfusion injury. Constitutive activation of the mitogen-activated protein kinase kinase 1 (CaMEK) can promote ERK1/2 expression, which is thereby expected to exert protective action on the heart against ischemia-reperfusion injury. The adeno-associated virus serotype 9 vector (AVV9) is a novel tool for gene therapies targeting human diseases owing to its nonpathogenic capability for transducing nondividing cells and its long-term transgene expression. We used a recombinant AAV9 vector to deliver the CaMEK gene into cardiomyocytes and assessed whether AAV9 vector-mediated CaMEK gene transfection could enhance the long-term expression and activity of ERK1/2. Our observations suggest that AAV9-mediated gene expression is preferentially restricted to cardiomyocytes and that mediated CaMEK gene transfection enhanced the expression of ERK1/2 phosphorylation and consequently upregulated the expression of downstream components of ERK1/2 and its transcription factors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23096919     DOI: 10.4238/2012.October.17.1

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  2 in total

1.  Sirt3 attenuates doxorubicin-induced cardiac hypertrophy and mitochondrial dysfunction via suppression of Bnip3.

Authors:  Qiong Du; Bin Zhu; Qing Zhai; Bo Yu
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

2.  Recombinant adeno-associated virus serotype 9 with p65 ribozyme protects H9c2 cells from oxidative stress through inhibiting NF-κB signaling pathway.

Authors:  Zhan Sun; Yi-Tong Ma; Bang-Dang Chen; Fen Liu
Journal:  J Geriatr Cardiol       Date:  2014-12       Impact factor: 3.327

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.